Emergent Biosolutions (NYSE:EBS) Share Price Passes Above 200-Day Moving Average – Here’s Why

Emergent Biosolutions Inc. (NYSE:EBS) shares passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $9.85 and traded as high as $12.05. Emergent Biosolutions shares last traded at $11.3350, with a volume of 566,824 shares.

Wall Street Analysts Forecast Growth

Several research firms have commented on EBS. Zacks Research raised shares of Emergent Biosolutions to a “hold” rating in a report on Friday, October 24th. Wall Street Zen upgraded shares of Emergent Biosolutions from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 30th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Emergent Biosolutions in a report on Tuesday, December 16th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Emergent Biosolutions in a report on Monday, December 29th. One analyst has rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, Emergent Biosolutions has an average rating of “Hold” and an average price target of $15.00.

Emergent Biosolutions Stock Performance

The company’s fifty day simple moving average is $11.97 and its 200 day simple moving average is $9.85. The company has a current ratio of 5.76, a quick ratio of 3.15 and a debt-to-equity ratio of 1.14. The stock has a market capitalization of $595.31 million, a P/E ratio of 8.72 and a beta of 2.30.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings data on Wednesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $1.18. Emergent Biosolutions had a return on equity of 20.85% and a net margin of 9.62%.The company had revenue of $231.10 million during the quarter, compared to analyst estimates of $203.67 million. As a group, sell-side analysts forecast that Emergent Biosolutions Inc. will post -0.63 earnings per share for the current fiscal year.

Insider Transactions at Emergent Biosolutions

In related news, Director Ronald Richard sold 21,984 shares of the stock in a transaction on Friday, December 5th. The stock was sold at an average price of $11.97, for a total value of $263,148.48. Following the transaction, the director owned 98,417 shares of the company’s stock, valued at $1,178,051.49. This represents a 18.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.20% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Legal & General Group Plc bought a new position in Emergent Biosolutions during the 2nd quarter worth approximately $31,000. Ameritas Investment Partners Inc. bought a new stake in Emergent Biosolutions in the second quarter valued at approximately $35,000. Torren Management LLC purchased a new stake in shares of Emergent Biosolutions during the fourth quarter valued at approximately $37,000. Raymond James Financial Inc. bought a new position in shares of Emergent Biosolutions in the second quarter worth approximately $53,000. Finally, Janney Montgomery Scott LLC purchased a new position in shares of Emergent Biosolutions in the second quarter worth $68,000. Hedge funds and other institutional investors own 78.40% of the company’s stock.

About Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.